<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="477">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 16, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01770665</url>
  </required_header>
  <id_info>
    <org_study_id>MAYO1000</org_study_id>
    <nct_id>NCT01770665</nct_id>
  </id_info>
  <brief_title>Validation of the MiCK Assay</brief_title>
  <acronym>MiCK Assay</acronym>
  <official_title>Mayo Clinic Validation of the MiCK Assay</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>DiaTech Oncology</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>DiaTech Oncology</source>
  <oversight_info>
    <authority>United States: Mayo Clinic IRB</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Testing Mayo Clinic cancer patients with the results being correlated with prior patient
      therapy, performance status, and extent of disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be conducted in two phases.

      During the Feasibility Phase, specimens from any tumor will be sent to the central DiaTech
      MiCK assay laboratory to determine the ease of sample acquisition, processing, transport,
      and assay interpretation.

      Once DiaTech has completed analyses for the feasibility phase specimens and has confirmed
      that the sample acquisition, processing, transport, and assay interpretation are
      appropriate, we will proceed with the Demonstration Phase.

      During the Mesothelioma Demonstration Phase, 20 mesothelioma samples will be assayed and the
      results will be correlated with prior patient therapy, performance status, and extent of
      disease.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Complete response and survival</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Mesothelioma, Small Cell Lung Cancer, NSCLC</condition>
  <arm_group>
    <arm_group_label>Mesothelioma</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>all cancer types</arm_group_label>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Human cancerous tumor.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        20 subjects diagnosed with mesothelioma and 10 diagnosed with any malignancy.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  20 subjects diagnosed with mesothelioma and 10 diagnosed with any malignancy.

        Exclusion Criteria:

          -  patients that a sample cannot obtained for testing.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary Karaus</last_name>
    <role>Study Director</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mary Karaus</last_name>
    <phone>507-538-8472</phone>
    <email>karaus.mary@mayo.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Validation Support Services 3050 Superior Drive NW</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Karaus</last_name>
      <phone>507-538-8472</phone>
      <email>karaus.mary@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Julian Molina, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dennis Wigle, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>April 18, 2014</lastchanged_date>
  <firstreceived_date>January 16, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
